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Abstract
Background: Survivin is an inhibitor of apoptosis protein and is involved in the occurrence and progression of human
malignancies. Recently, a functional polymorphism (231G.C, rs9904341) in the promoter of survivin has been shown to
influence its expression and confer susceptibility to different types of cancer. The present study was aimed to investigate
whether the polymorphism also influences susceptibility and progression of renal cell cancer (RCC) in a Chinese population.
Methods: We genotyped this polymorphism using the TaqMan assay in a case-control study comprised of 710 RCC patients
and 760 controls. The logistic regression was used to assess the genetic association with occurrence and progression of RCC.
Results: Compared with the genotypes containing G allele (GG and GC), we found a statistically significant increased
occurrence of RCC associated with the CC genotype [P=0.006, adjusted odds ratio (OR)=1.38, 95% confidence interval
(CI)=1.08–1.76]. The polymorphism was associated with risk of developing advanced stage (OR=2.02, 95%CI=1.34–3.07)
and moderately differentiated (OR=1.75; 95%CI=1.20–2.54) RCC. Furthermore, the patients carrying the CC genotype had a
significantly greater prevalence of high clinical stage disease (Ptrend=0.003). Similar results were also observed when we
restricted the analysis to clear cell RCC, a major histological type of RCC.
Conclusions: Our results suggest that the functional 231G.C polymorphism in the promoter of survivin may influence the
susceptibility and progression of RCC in the Chinese population. Large population-based prospective studies are required to
validate our findings.
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Introduction
Renal cell cancer (RCC) accounts for more than 90% of all renal
malignancies [1]. The incidence rates of RCC vary among different
populations, with higher rates in Europeans and lower rates in Asians
[1]. The exact causes of RCC are poorly understood. To date, only a
few risk factors for RCC have been established, including cigarette
smoking, obesity, hypertension and diabetes [1]. Renal tumorigenesis
is a complex process determined by the interactions between
environmental and genetic factors [2]. The identification of genetic
susceptibility of RCC, although is still needed further investigation,
has enlightened the molecular pathogenesis of this disease [1,3,4,5]. It
also has been suggested that genetic variation in candidate-genes
influenced the progression and prognosis of RCC [6,7,8,9].
Dysregulation of apoptosis has been implicated in carcinogen-
esis through abnormally prolonging cell survival and facilitating
the accumulation of transforming mutations[10]. Survivin is a
structurally unique member of the inhibitor of apoptosis protein
family that suppresses apoptosis and regulates cell division [11,12].
Over-expression of survivin was frequently observed in a variety of
human malignancies [11], such as colorectal cancer [13], lung
cancer [14], hepatocelluar carcinoma [15], pancreatic cancer [16],
and osteosarcoma [17]. Besides, over-expression of survivin is
correlated with poor prognosis of these cancers. It has been
demonstrated that sufficient expression of survivin messenger
RNA and protein were detected in RCC cell lines but not in
normal human kidney epithelial cell line [18]. Elevated expression
of survivin was also observed in RCC tissues compared with
adjacent normal tissues [18,19]. For the outcome of RCC patients,
over-expression of survivin was significantly associated with
advanced tumor stage, tumor grade and lymph node metastasis
[19,20]. Besides, RCC patients with high survivin levels had a
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[21,22].
Recently, a 231G.C (rs9904341) single-nucleotide polymor-
phism, which is located at the cell cycle-dependent elements (CDE)
and cell cycle homology regions (CHR) repressor binding site of
the survivin promoter, has been demonstrated to influence survivin
expression by modifying the binding affinity of the CDE/CHR
repressor [23,24]. The 231G allele was shown to have a
significantly lower transcriptional activity than the 231C allele
[25]. To date, several epidemiological studies have suggested that
this polymorphism was associated with the risk and/or prognosis
of various carcinomas [26]. However, the role of this polymor-
phism in the etiology of RCC has never been specifically
investigated before. Considering the crucial role that survivin
plays in the occurrence and progression of RCC, we hypothesized
that the functional 231G.C polymorphism in the promoter of
survivin could be a potentially genetic marker to predict RCC risk
and progression. To test this hypothesis, we genotyped this
polymorphism in a case-control study comprised of 710 cases and
760 controls in a Chinese population and assessed the genetic
association with occurrence and progression of RCC using logistic
regression analysis.
Materials and Methods
Ethics Statement
The study was approved by the Institutional Review Board of
the Nanjing Medical University, Nanjing, China. At recruitment,
written informed consent was obtained from all participants
involved in this study.
Study population
This is an ongoing molecular epidemiologic study of RCC
conducted in the First Affiliated Hospital of Nanjing Medical
University, Nanjing, China, from May 2004. The design of the
study and the inclusion criteria of the subjects were previously
described elsewhere [6]. In brief, all subjects in our study are
ethnic Han Chinese coming from different families and have no
blood relationship. All the patients were newly diagnosed with
histopathologically confirmed, incident RCC without prior history
of other cancers or previous chemotherapy or radiotherapy, and
were consecutively recruited without restriction of age and sex.
Disease was classified according to World Health Organization
criteria and staged according to the American Joint Committee on
Cancer TNM classification. The Fuhrman scale was used to assess
tumor nuclear grade. Histological sections of all cases were
reviewed by two pathologists independently. The controls were
recruited from healthy subjects who were seeking physical
examination in the outpatient departments at the hospital and
were frequency-matched to the cases on age (65 years) and sex.
Hypertension was defined as systolic BP (SBP)$140 mmHg and/
or diastolic BP (DBP)$90 mmHg, and/or being on drug therapy.
Diabetes diagnosis was measured as self reported earlier diagnosis,
fasting blood glucose $6.1 mmol/l, and/or treatment for earlier
diagnosed diabetes mellitus. Compared to our previously pub-
lished studies [6], a further 90 cases and 137 controls recruited
recently were added to the present study.
DNA extraction and polymorphism genotyping
Total genomic DNA was extracted from the peripheral blood
by proteinase K digestion and phenol–chloroform extraction. The
genotyping of the 231G.C polymorphism (rs9904341) was
carried out using predesigned TaqMan SNP Genotyping Assays
(Applied Biosystems, Foster City, CA, USA). The primer and
probe sequences are summarized in Table S1. Amplification was
performed under the following conditions: 50uC for 2 min, 95uC
for 10 min followed by 45 cycles of 95uC for 15 sec, and 60uC for
1 min. According to the manufacturer’s instructions, amplifica-
tions and analysis were carried out in the 384-well ABI 7900HT
Real-Time PCR System (Applied Biosystems) and the SDS 2.4
software were used for allelic discrimination. For quality control,
four negative controls were included in each plate and 5% of the
samples were randomly selected for repeated genotyping for
confirmation; and the results were 100% concordant.
Statistical analysis
The differences in categorical variables such as gender, smoking
status, drinking status, and in the frequency distribution of
231G.C alleles and genotypes between the cases and controls
were evaluated by Pearson’s chi-square test. The differences in
continuous variables such as age and BMI were tested by Student’s
t-test. Before analysis, allele frequencies of the 231G.C
polymorphism in the controls was tested against departure from
the Hardy-Weinberg Equilibrium (HWE) using the Goodness-of-
fit Chi-square test. Associations between the 231G.C polymor-
phism and RCC risk were evaluated by computing odds ratios
(ORs) and 95% confidence intervals (CIs) from unconditional
logistic regression analysis with the adjustment for possible
confounders. A two-side P value of less than 0.05 was considered
as statistically significant. All the analyses were carried out with the
software SAS 9.1.3 (SAS Institute, Cary, NC, USA).
Results
The selected characteristics between the RCC patients and
control subjects are presented in Table 1. The cases and controls
appeared to be well matched on age and sex (P=0.753 and 0.832,
respectively). Moreover, no significant differences were observed
between the cases and controls with regards to BMI and drinking
status (P=0.078 and P=0.120, respectively). However, more
smokers, hypertension patients and diabetics were presented in the
cases compared with controls (P=0.035, ,0.001 and ,0.001,
respectively). The majority of patients (84.8%) had the conven-
tional clear cell cancer. When stratified according to the clinical
stage, 62.8%, 19.6%, 7.3% and 10.3% of the patients had stage I,
II, III and IV disease, respectively. The percent of nuclear grade
from I to IV was 19.2%, 48.0%, 24.5%, and 8.3%, respectively.
The genotype and allele frequencies of the 231G.C
polymorphism are shown in Table 2. The genotype frequencies
in controls and patients both conformed to HWE (P=0.467 and
0.610, respectively). The frequencies of the GG, GC and CC
genotypes among cases were significantly different from those
among controls (P=0.015). The difference in the frequencies
distribution of G and C allele among case and controls was also
significant (P=0.006). Compared with individuals carrying G
allele (GG/GC), individual with CC genotype had a significantly
increased susceptibility to RCC occurrence (OR=1.38,
95%CI=1.08–1.76, P=0.006). Furthermore, the variant 231C
allele was also associated with an increased risk for RCC,
compared with the 231G allele (OR=1.11, 95%CI=1.03–
1.20, P=0.006). Similar results were observed when we restricted
the analysis to clear cell RCC (Table 2). These results suggested
that the survivin 231G.C polymorphism had effect on RCC
occurrence.
We then evaluated the effect of the polymorphism on RCC risk
stratified by age, BMI, sex, smoking status, smoking level and
drinking status. The results were summarized in Table S2.
Although the increased risk appeared to be more evident in the
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drinkers, no significant heterogeneity between the subgroups was
observed which implicated independent genetic effects (all
Pheterogeneity.0.05). We then examined the effects of the
polymorphism on the progression of RCC. As presented in
Table 3, the 231CC genotype was associated with risk of
developing advanced stage RCC (OR=2.02, 95%CI=1.34–3.07)
and moderately-differentiated RCC (OR=1.75; 95%CI=1.20–
2.54). As shown in Table 4, in the case group, patients carrying the
CC genotype had a significantly greater prevalence of high clinical
stage disease (P=0.021 for RCC and P=0.018 for ccRCC) in a
dose–response manner (Ptrend=0.003). However, no association
between this polymorphism and tumor grade in cases was
observed (P=0.379 for RCC, P=0.700 for ccRCC).
Discussion
In the present study, we evaluated the associations between the
functional 231G.C polymorphism in the promoter of survivin and
risk and progression of RCC. We found that individuals with the
231CC genotype had a significantly increased RCC risk of 1.50
and 1.38, compared with those with GG or GG/GC genotypes,
respectively. The polymorphism was also associated with risk of
developing advanced stage and moderately-differentiated RCC.
Besides, we found that RCC patients carrying the CC genotype
had a significantly greater prevalence of high clinical stage disease,
compared with those with GG/GC genotypes. To the best of our
knowledge, this is the first study to investigate the role of the
survivin -31G.C polymorphism in the etiology of RCC.
As a unique inhibitor of apoptosis protein, survivin reduces the
susceptibility of tumor cells to apoptotic stimuli and thereby
promotes tumor cell survival during tumor development and
progression [11,12]. Survivin is strongly expressed in fetal tissues,
but not expressed in adult normal tissues [27,28]. However, over-
expression of survivin was frequently observed in different types of
cancer, including RCC. Lei et al. have demonstrated that the
expression of survivin was elevated both in RCC cell lines and in
tumor tissues [18]. Recently, several studies have suggested that
the survivin promoter 231G.C polymorphism could modulate the
expression of survivin [25,29]. As mentioned before, this
polymorphism is located at the CDE/CHR repressor binding site
and may influence the affinity of repressor binding to this region,
and then affect the expression of survivin. Functional studies have
demonstrated that the 231C allele displayed a significantly higher
transcriptional activity than the 231G allele, and individuals with
the 231CC genotype had an increased survivin levels than those
carrying the GC and GG genotypes [25]. Since survivin functions
as an inhibitor of apoptosis protein that plays a crucial role in
eliminating mutated or transformed cells from body, it is possible
that individuals carrying the higher production genotype of survivin
231G.C polymorphism may possess a decreased apoptotic
capacity to eliminate cells with DNA damage which may
contribute to the occurrence of malignancies. Therefore, it is
biologically plausible that the survivin promoter 231G.C
polymorphism confers individuals susceptibility to RCC.
To date, a number of studies have attempted to evaluate the
associations of the survivin 231G.C polymorphism and cancer
risk [26]. The correlation between the survivin 231CC genotype
and increased cancer risk has been identified by several other
studies [26]. Although the role of this polymorphism in the
etiology of RCC has not been assessed before, there are studies
reporting that the survivin 231CC genotype was associated with
increased risk of other urinary system cancer, such as urothelial
carcinoma (OR=4.0, 95%CI=2.3–7.2) [30] and bladder cancer
(OR=1.85, 95%CI=1.27–2.70) [31]. Our results are comparable
to the results of these two studies and further suggest an important
role of the survivin 231G.C polymorphism in the development of
urinary system cancer. Most recently, a meta-analysis study has
been conducted by Srivastava et al. to clarify the associations of this
polymorphism and cancer risk [26]. They found that the survivin
231C allele was associated with 1.27 fold increased risk of cancer.
The magnitude of RCC risk found with the C allele or CC
genotype in the present study (OR=1.11 and 1.38, respectively)
were similar to the risk observed in the meta-analysis. However,
Table 1. Distribution of selected variables between the renal
cell cancer cases and the control subjects.
Variables Cases (n=710) Controls (n=760) P
*
N% N%
Age (mean 6 SD), years 56.9611.9 56.8611.6 0.753
#57 364 51.3 423 55.7 0.092
.57 346 48.7 337 44.3
BMI (mean 6 SD), kg/m
2 24.162.8 23.863.2 0.078
,24 346 48.7 391 51.5 0.298
$24 364 51.3 369 48.5
Sex
Male 454 63.9 490 64.5 0.832
Female 256 36.1 270 35.5
Smoking status
Never 444 62.5 515 67.8 0.035
Ever 266 37.5 245 32.2
Drinking status
Never 508 71.6 571 75.1 0.120
Ever 202 28.5 189 24.9
Hypertension
No 444 62.5 444 73.0 ,0.001
Yes 266 37.5 205 27.0
Diabetes
No 611 86.1 716 94.2 ,0.001
Yes 99 13.9 44 5.8
Clinical stage
I 446 62.8
II 139 19.6
III 52 7.3
IV 73 10.3
Grade
I 136 19.2
II 341 48.0
III 174 24.5
IV 59 8.3
Histology
Clear cell 602 84.8
Papillary 22 3.1
Chromophobe 39 5.5
Unclassified 47 6.6
*Student’s t-test for age and BMI distributions between cases and controls; two-
sided x2 test for other selected variables between cases and controls.
doi:10.1371/journal.pone.0028829.t001
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susceptibility locus for RCC by the recently published genome-
wide association studies in European populations [3,5]; and in our
study, the p-value for the association between the polymorphism
and RCC risk also did not meet genome-wide statistical
significance. The survivin 231G.C polymorphism was not
included in the GWAS conducted by Purdue et al [3], however,
the GWAS results for a surrogate (rs3764384) in perfect with the
231G.C polymorphism was available. In their GWAS, the
rs3764384 was not associated with RCC risk (P=0.220,
OR=1.07, 95%CI=0.96–1.18). According to the HapMap
database, the rs3764384 is in complete linkage disequilibrium
with the survivin 231G.C polymorphism in both Chinese Han
populations and Caucasian populations (D9=1,r
2=1); the minor
allele frequency of 231G.C (G allele) in Chinese Han population
in Beijing is 0.477, which is dramatically different from that in
European population (0.717). Therefore, we speculate that
ethnicity differences might play a role in causing the disparity.
It has been proposed that expression level of survivin was a
biomarker to predict RCC progression and prognosis [32]. Several
studies have reported that elevated expression of survivin was
associated with advanced tumor stage and grade, and patients with
high survivin levels had a significantly shorter overall survival time
than those with low survivin levels [20,21,22]. In the present study,
we observed that that the survivin 231CC genotype was associated
with progression of RCC, but these results should be interpreted
cautiously since there is the possibility that the associations with
poor prognosis are due to a late stage at diagnosis. Therefore, if
confirmed by additional studies, this polymorphism may help to
accurately predict the clinical course of RCC patients. RCC is
characterized by high intra-tumor vascularity and, so far several
anti-angiogenesis drugs (bevacizumab, pazopanib and sorafenib)
have proven benefit in treating advanced RCC [33]. Since
survivin has been suggested to promote tumor-associated angio-
genesis and acts as a resistance factor to various anticancer
therapies [34,35], if individuals’ drug susceptibility can be
predicted by genetic variation such as the survivin 231G.C
polymorphism, the efficacy of these drugs may be further
enhanced. However, lack of available information on the drug
treatment of our RCC patients and long-term follow-up restricts
our study to explore the influence of the survivin 231G.C
polymorphism on the efficacy of these drugs. Therefore, we urge
that it be investigated in other studies which focus on the treatment
of RCC patients.
Table 2. Genotype and allele frequencies of survivin 231G.C polymorphism among the cases and controls and the associations
with risk of renal cell cancer.
Genotypes Controls, n (%) Renal cell cancer patients Clear cell renal cell cancer patients
N( % ) P
* OR (95% CI)
* n( % ) P
* OR (95% CI)
*
231G.C
GG 215 (28.3) 172 (24.2) 0.008 1.00 (reference) 147 (24.4) 0.022 1.00 (reference)
GC 385 (50.7) 345 (48.6) 1.14 (0.89–1.47) 295 (49.0) 1.14 (0.88–1.49)
CC 160 (21.0) 193 (27.2) 1.50 (1.12–2.02) 160 (26.6) 1.42 (1.07–1.98)
Ptrend 0.006
GG+GC 600 (79.0) 517 (72.8) 0.011 1.00 (reference) 443 (73.4) 0.032 1.00 (reference)
CC 160 (21.0) 193 (27.2) 1.38 (1.08–1.76) 159 (26.4) 1.32 (1.02–1.71)
G allele 815 (53.6) 689 (48.5) 0.006 1.00 (reference) 590 (49.0) 0.017 1.00 (reference)
C allele 705 (46.4) 731 (51.5) 1.23 (1.06–1.42) 614 (51.0) 1.20 (1.03–1.40)
*Adjusted for age, sex, BMI, smoking status, drinking status, diabetes and hypertension in logistic regression model. CI, confidence interval; OR, odds ratio.
doi:10.1371/journal.pone.0028829.t002
Table 3. The associations between survivin 231G.C polymorphism and the progression of renal cell cancer.
Categories Renal cell cancer patients Clear cell renal cell cancer patients
CG+GG CC P
* OR (95% CI)
* CG+GG CC P
* OR (95% CI)
*
Controls (n=760) 600 (79.0) 160 (21.0) 0.011 1.38 (1.08–1.76) 600 (79.0) 160 (21.0) 0.032 1.32 (1.02–1.71)
Cases (n=710)
Clinical stage
Localized (I+II) 437 (74.7) 148 (25.3) 0.096 1.25 (0.96–1.62) 388 (75.2) 128 (24.8) 0.145 1.22 (0.93–1.60)
Advanced (III+IV) 80 (64.0) 45 (36.0) 0.001 2.02 (1.34–3.07) 54 (62.8) 32 (37.2) 0.001 2.20 (1.36–3.56)
Grade
Well-differentiated (I+II) 354 (74.2) 123 (25.8) 0.088 1.27 (0.97–1.67) 319 (74.7) 108 (25.3) 0.119 1.25 (0.94–1.67)
Moderately-differentiated (III) 118 (67.8) 56 (32.2) 0.004 1.75 (1.20–2.54) 98 (70.0) 42 (30.0) 0.030 1.58 (1.05–2.39)
Poorly-differentiated (IV) 45 (76.3) 14 (23.7) 0.649 1.16 (0.61–2.19) 25 (71.4) 10 (28.6) 0.269 1.54 (0.72–3.30)
*Adjusted for age, sex, BMI, smoking status, drinking status, diabetes and hypertension in logistic regression model. CI, confidence interval; OR, odds ratio.
doi:10.1371/journal.pone.0028829.t003
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concerned. Because our case-control study was a hospital-based
study, we could not rule out a possibility of selection bias of
subjects that may have been associated with a particular genotype.
However, the 231C allele frequency in our controls was similar to
that in the HapMap database for Han Chinese in Beijing (46.4%
vs. 48.8%) and was also similar to that in another population-
based case-control study of Chinese population (46.4% vs. 47.6%).
Besides, the genotype distributions of the polymorphism in our
controls conformed to HWE. Therefore, the selection bias in terms
of genotype distributions would not be substantial.
In conclusion, our case–control study indicates that the
231G.C polymorphism in the promoter of survivin have a
significant influence on the occurrence and progression of RCC in
Chinese population. Although the associations appeared to be
statistically significant in our population, these initial findings
should be independently verified by other large independent
population-base studies. Besides, polymorphisms often vary
between ethnic groups; therefore, additional studies are also
required to clarify the association of this polymorphism with RCC
risk in diverse ethnic populations.
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